Case report: Beyond arrhythmia: STAR-inspired single-fraction cardiac radioablation for Ewing sarcoma metastasis - Takeaways - MDSpire

Case report: Beyond arrhythmia: STAR-inspired single-fraction cardiac radioablation for Ewing sarcoma metastasis

  • By

  • Erika Galietta

  • Silvia Strolin

  • Lidia Strigari

  • Francesco Cellini

  • Savino Cilla

  • Leonardo Santarelli

  • Vincenzo Russo

  • Alessandra Arcelli

  • Cristian Martignani

  • Costanza Maria Donati

  • Alessio G. Morganti

  • Silvia Cammelli

  • June 30, 2026

  • 0 min

Share

  • 1

    Stereotactic arrhythmia radioablation (STAR) is effective for refractory ventricular arrhythmias and may be applicable for oncologic cardiac targets.

  • 2

    A 26-year-old man with metastatic Ewing sarcoma underwent STAR-inspired single-fraction cardiac radioablation for a right-ventricular mass.

  • 3

    The patient received 25 Gy in a single fraction, resulting in a reduction of the lesion size from 17 × 15 mm to 8 × 10 mm at 12 months.

  • 4

    No cardiac toxicity was observed, and the patient remained free of cardiac symptoms and disease progression at 31 months post-treatment.

  • 5

    The case supports further evaluation of STAR-inspired approaches for treating unresectable cardiac tumors.

Original Source(s)

Case report: Beyond arrhythmia: STAR-inspired single-fraction cardiac radioablation for Ewing sarcoma metastasis

  • by Erika Galietta, Silvia Strolin, Lidia Strigari, Francesco Cellini, Savino Cilla, Leonardo Santarelli, Vincenzo Russo, Alessandra Arcelli, Cristian Martignani, Costanza Maria Donati, Alessio G. Morganti, Silvia Cammelli

  • June 30, 2026

Related Content

ESMO Breast Cancer 2026 Highlights: TRAK-ER

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Clinical evaluation of large language model recommendations in melanoma: comparison with multidisciplinary tumor board decisions in a real-world cohort